Coya Therapeutics, Inc. financial data

Symbol
COYA on Nasdaq
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 907% % -8.58%
Debt-to-equity 15% % 10%
Return On Equity -57% % -81.34%
Return On Assets -50% % -79.13%
Operating Margin -517% % -334.79%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20,924,456 shares 25%
Common Stock, Shares, Outstanding 16,742,638 shares 10%
Entity Public Float $85,212,539 USD 134%
Common Stock, Value, Issued $1,675 USD 10%
Weighted Average Number of Shares Outstanding, Basic 16,732,766 shares 9.9%
Weighted Average Number of Shares Outstanding, Diluted 16,732,766 shares 9.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $3,987,706 USD -58.26%
General and Administrative Expense $10,317,488 USD 13%
Operating Income (Loss) $-20,604,632 USD -81.47%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $-6,094,977 USD -110.78%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $-18,433,341 USD -72.29%
Earnings Per Share, Basic -1 USD/shares -68.18%
Earnings Per Share, Diluted -1 USD/shares -68.18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $28,129,866 USD -9.43%
Assets, Current $32,024,810 USD -9.81%
Property, Plant and Equipment, Net $18,068 USD -60.23%
Assets $32,042,878 USD -9.87%
Accounts Payable, Current $1,111,702 USD 230%
Accrued Liabilities, Current $1,638,706 USD 16%
Liabilities, Current $3,667,120 USD 58%
Liabilities $4,758,387 USD 34%
Retained Earnings (Accumulated Deficit) $-56,254,735 USD -48.74%
Stockholders' Equity Attributable to Parent $27,284,491 USD -14.76%
Liabilities and Equity $32,042,878 USD -9.87%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-2,828,275 USD -231.8%
Net Cash Provided by (Used in) Financing Activities $19,137 USD -98.46%
Net Cash Provided by (Used in) Investing Activities $-25,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 16,742,638 shares 10%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $8,129,074 USD 45%
Depreciation $27,360 USD -0%
Property, Plant and Equipment, Gross $136,804 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $1,351,896 USD 208%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $83,537,551 USD 20%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $3,977,236 USD 88%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%